Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026

About this update from Daiichi Sankyo Company, Limited

MUNICH, May 26, 2026 --( BUSINESS WIRE )--Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment in cardiovascular health and its mission to care for every heartbeat. The 15-abstract showcase provides a comprehensive look at the role of bempedoic acid in lipid management. This includes post-hoc analyses in collaboration with Esperion Therapeutics from the Phase 3 CLEAR Outcomes trial exploring its impact on stroke and venous thromboembolism (VTE) incidence. 5,6 There are also real-world findings from the MILOS registry, including a dedicated sub-analysis investigating the effectiveness of bempedoic acid across various background therapies. 1,2,3,4 Results reinforce consistent effectiveness and safety profile of bempedoic acid across various EU countries and regardless of patients’ existing treatment regimens. 7 DSE’s commitment to expanding the evidence base for bempedoic acid is further reflected in new Esperion sponsored data being presented in paediatric patients (aged 6–17 years old) with familial hypercholesterolemia. 8 Alongside the recent label update regarding breastfeeding – where use may now be considered by weighing the benefit of therapy for the mother against the child’s benefit from breastfeeding – these milestones underscore DSE’s ongoing efforts to study bempedoic acid across all populations, including specific underserved groups, to ensure as many patients as possible can achieve their LDL-C goals. 9,10 "Far too many patients across Europe still fail to reach their LDL-C targets, leaving them unnecessarily exposed to cardiovascular risk," says Prof. Maurizio Averna, Professor of Internal Medicine, School of Medicine, University of Palermo, Italy. "The real-world data being presented at EAS 2026 provide critical evidence to help clinicians bridge these treatment gaps in routine practice and improve outcomes for a diverse range of patients." "At Daiichi Sankyo Europe, our commitment goes beyond clinical data; it is rooted in the individual journey of every patient," said Dr. Stefan Seyfried, Vice President and Head of Medical Affairs, Specialty Medicines, Daiichi Sankyo Europe. "The extensive data set we are presenting at EAS 2026 – a testament to our sustained investment in cardiovascular health – reinforces our mission to give every patient a chance to reach their treatment goals. By translating scientific innovation into practical, patient-centred care, we are ensuring that we care for every heartbeat through innovative and accessible solutions." By emphasizing bempedoic acid’s ability to deliver improved cardiovascular outcomes and low-density lipoprotein cholesterol (LDL-C) reduction, irrespective of background therapy and patient subgroup, DSE aims to ensure that healthcare professionals have the evidence needed to support their lipid management treatment decisions. Data Being Presented at EAS Congress 2026 MILOS study CLEAR Outcomes trial CLEAR Path 1 trial About MILOS MILOS (NCT04579367) is an ongoing, multinational, European observational study in adult patients diagnosed with primary hypercholesterolaemia or mixed dyslipidaemia. 11 The aim is to evaluate the real-world use of bempedoic acid and bempedoic plus ezetimibe fixed-dose combination. Beyond Germany, MILOS has sites in Austria, Belgium, Italy, the Netherlands, Spain, Switzerland and the UK. 11 About CLEAR Outcomes trial The CLEAR Outcomes trial was a double‑blind, randomized, placebo‑controlled study designed to evaluate the effect of bempedoic acid on cardiovascular (CV) outcomes in statin‑intolerant patients for whom primary or secondary CV prevention was clinically indicated. 12 The trial enrolled 13,970 patients aged 18–85 years (mean age 65.5 years), nearly half of whom were women, all of whom had established or were at high risk for cardiovascular disease and a mean baseline LDL‑C of 139 mg/dL (3.59 mmol/L). 12 Conducted at 1,250 sites across 32 countries, patients were randomized to receive oral bempedoic acid 180 mg daily or placebo and were followed for a median of 40.6 months. 12 The primary endpoint was a four‑component composite of major adverse cardiovascular events (MACE‑4): CV death, non‑fatal myocardial infarction, non‑fatal stroke, or coronary revascularization, with multiple key secondary CV endpoints also assessed. 12 About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit www.daiichisankyo.com . References View source version on businesswire.com: https://www.businesswire.com/news/home/20260526953274/en/ Contacts Media Contact Shreya Pandey Daiichi Sankyo Europe GmbH Senior Public Relations Manager +49 151 54478370

View stock analysis, news, and events for Daiichi Sankyo Company, Limited